Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells

Background:There is variability in the cancer phenotype across individuals: two patients with the same tumour may experience different disease life histories, resulting from genetic variation within the tumour and from the interaction between tumour and host. Until now, phenotypic variability has precluded a clear-cut identification of the fundamental characteristics of a given tumour type.Methods:Using multiple myeloma as an example, we apply the principles of evolutionary game theory to determine the fundamental characteristics that define the phenotypic variability of a tumour.Results:Tumour dynamics is determined by the frequency-dependent fitness of different cell populations, resulting from the benefits and costs accrued by each cell type in the presence of others. Our study shows how the phenotypic variability in multiple myeloma bone disease can be understood through the theoretical approach of a game that allows the identification of key genotypic features in a tumour and provides a natural explanation for phenotypic variability. This analysis also illustrates how complex biochemical signals can be translated into cell fitness that determines disease dynamics.Conclusion:The present paradigm is general and extends well beyond multiple myeloma, and even to non-neoplastic disorders. Furthermore, it provides a new perspective in dealing with cancer eradication. Instead of trying to kill all cancer cells, therapies should aim at reducing the fitness of malignant cells compared with normal cells, allowing natural selection to eradicate the tumour.

[1]  Arne Traulsen,et al.  Multiple mutant clones in blood rarely coexist. , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.

[2]  K. Moriyama,et al.  Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. , 2004, Blood.

[3]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[4]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[5]  Josef Hofbauer,et al.  Evolutionary Games and Population Dynamics , 1998 .

[6]  C. Dinarello Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. , 2009, Mayo Clinic proceedings.

[7]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[8]  G. Roodman,et al.  Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.

[9]  J M Smith,et al.  Evolution and the theory of games , 1976 .

[10]  Arne Traulsen,et al.  On the Origin of Multiple Mutant Clones in Paroxysmal Nocturnal Hemoglobinuria , 2007, Stem cells.

[11]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[12]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[13]  I. Tomlinson,et al.  Game-theory models of interactions between tumour cells. , 1997, European journal of cancer.

[14]  B. Barlogie,et al.  Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. , 2008, Bone.

[15]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[16]  北村 聖 "The New England Journal of Medicine". , 1962, British medical journal.

[17]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[18]  D. Jelinek,et al.  Mechanisms of myeloma cell growth control. , 1999, Hematology/oncology clinics of North America.

[19]  T. Weber,et al.  SECONDARY OSTEOPOROSIS : Diagnostic Considerations , 1998 .

[20]  E. Terpos,et al.  New insights into the pathophysiology and management of bone disease in multiple myeloma , 2003, British journal of haematology.

[21]  Toshio Matsumoto,et al.  Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma , 2004, British journal of haematology.

[22]  M. Dimopoulos,et al.  Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.

[23]  J. Epstein,et al.  Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.

[24]  Bart Barlogie,et al.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.

[25]  W. F. Bodmer,et al.  Modelling the consequences of interactions between tumour cells. , 1997, British Journal of Cancer.

[26]  G. Roodman Pathogenesis of myeloma bone disease , 2009, Leukemia.

[27]  X. Mariette,et al.  The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression , 2004, Leukemia & lymphoma.

[28]  J. Berenson Bone disease in myeloma , 2001, Current treatment options in oncology.

[29]  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.

[30]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[31]  K. Vanderkerken,et al.  The role of the bone marrow microenvironment in multiple myeloma. , 2005, Histology and histopathology.

[32]  O. Stephens,et al.  Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. , 2008, Blood.

[33]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[34]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.

[35]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[36]  G. Roodman,et al.  Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease , 2001 .

[37]  D. Dingli,et al.  In vivo and in silico studies on single versus multiple transplants for multiple myeloma , 2007, Cancer science.

[38]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.

[39]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Dingli,et al.  Serum M‐spike and transplant outcome in patients with multiple myeloma , 2007, Cancer science.

[42]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .